Loading data for CMPS — first visit, this takes a few seconds.
COMPASS Pathways (CMPS)
NasdaqGS: CMPS
· Real-Time Price · USD
13.73
-0.91 (-6.22%)
At close: Aug 28, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
COMPASS Pathways (CMPS) Stock Price, Analysis & Data
-6.22% (1D)
No data available
| Bid | 10.39 |
| Market Cap | 1.9B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -394.19M |
| 2.53 | |
| -3.55 | |
| n/a | |
| -9.58 | |
| P/B (ttm) | 22.04 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 3, 2026 |
| Ask | 17.56 |
| Volume | 2,643,279 |
| Avg. Volume (20D) | 3,612,580 |
| Open | 14.60 |
| Previous Close | 14.64 |
| Day's Range | 13.69 - 14.71 |
| 52-Week Range | 4.40 - 15.40 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CMPS
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to...
Industry Medical Care Facilities
Sector Healthcare
IPO Date Sep 18, 2020
Employees 156
Stock Exchange NasdaqGS
Ticker Symbol CMPS
Website https://compasspathways.com
Financial Performance
In 2025, COMPASS Pathways's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -287.86M, an increase of 85.57%.
Financial StatementsEarnings Surprise
COMPASS Pathways has released their quarterly earnings on Aug 5, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.36 misses estimates by -0.03, with 12.20% YoY growth.
COMPASS Pathways is scheduled to release its earnings on Nov 3, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2